Our earlier study thus suffered from the potential drawback that the initial screening would enrich for tumors with large HER2 positive areas, and that cancers with HER2 negative status on one 0.6 mm spot were not validated to exclude small HER2 positive cancer areas. This evidence concerns the gene ERBB2 and cancer.